Overview

Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if lenalidomide (Revlimid®) can help to control CLL in patients who have already received standard therapy. The safety of lenalidomide will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Celgene Corporation
Treatments:
Lenalidomide
Thalidomide